Bio-Path Holdings Presents Ongoing Phase 2 Combination Study Data at ASCO Annual Meeting
DENVER, Colo., Jun 03, 2024 (247marketnews.com)- Maro Ohanian, D.O., Department of Leukemia, University of Texas MD Anderson Cancer Center, presented ongoing Phase 2 study of prexigebersen (BP1001) interim results at the American Society of Clinical Oncology (ASCO) Annual Meeting, on June 1, 2024, on behalf of Bio-Path Holdings, Inc. (NASDAQ:BPTH)
“We were honored to have our data selected for oral presentation at ASCO as it underscores not only the quality of our data, but also highlights the continued unmet need for these most vulnerable cancer patients,” stated Bio-Path’s CEO, Peter Nielsen. “We continue to advance this important study confident that prexigebersen can make a difference in the lives of these patients for whom there are limited treatment options.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (BPTH)
- Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum
- Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25
- Bio-Path Holdings Provides Clinical and Operational Update
- Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
- Bio-Path Holdings Reports Full Year 2024 Financial Results